When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and ...

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy ...

Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Research using heart cells from squirrels, mice and people ...

ATLANTA, GA—Ninerafaxstat (Imbria Pharmaceuticals), a novel drug targeted at patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), is safe and well tolerated, according to data ...

EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure -- ...

The heart's ability to beat normally over a lifetime is predicated on the synchronized work of proteins embedded in the cells of the heart muscle. Like a fleet of molecular motors that get turned on ...

Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Gene defect that affects a protein found in the heart muscle ...

Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, announced the dosing of the first patient in the phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel oral, ...

Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart and a leading cause of sudden cardiac death in young people and athletes. Scientists have long known that the ...

Hypertrophic cardiomyopathy (HCM) is the most common of all genetic heart diseases and is the leading cause of sudden cardiac death. It is characterized by an abnormal thickening of the heart muscle, ...